Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 133,828,000, a decrease of 3% from RMB 139,146,000 in the same period of 2023[2] - The gross profit for the same period was RMB 58,531,000, down 12% from RMB 66,676,000 year-on-year[2] - Operating loss increased to RMB 11,951,000 compared to a loss of RMB 5,490,000 in the prior year[2] - The net loss for the period was RMB 18,314,000, which is a significant increase from RMB 8,011,000 in the previous year[2] - Basic and diluted loss per share was RMB 0.091, compared to RMB 0.037 in the same period last year[2] - The total comprehensive loss for the six months ended June 30, 2024, was RMB (18,337,000), compared to RMB (7,956,000) for the same period in 2023, reflecting an increase in losses[6] - The company reported a loss of approximately RMB 18.3 million for the reporting period, compared to a loss of RMB 8 million in the same period last year[37] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 538,339,000, a slight decrease from RMB 563,151,000 as of December 31, 2023[4] - Current liabilities totaled RMB 311,085,000, down from RMB 320,747,000 at the end of 2023[5] - The company’s cash and cash equivalents decreased to RMB 35,076,000 from RMB 63,410,000 at the end of the previous year[4] - Non-current assets amounted to RMB 212,552,000, slightly down from RMB 213,111,000 at the end of 2023[4] - The company reported a total equity of RMB 213,067,000, down from RMB 231,404,000 at the end of the previous year[5] - Trade receivables at the end of the reporting period amounted to RMB 177,518,000, a decrease from RMB 179,798,000 at the end of 2023[21] - Trade payables at the end of the reporting period were RMB 108,517,000, down from RMB 111,540,000 at the end of 2023[22] - The company’s bank loans totaled RMB 141,312,000, a slight decrease from RMB 142,717,000 in the previous year[23] - The company has a guarantee of RMB 6,000,000 for a loan granted to a subsidiary, down from RMB 10,000,000 at the end of 2023[25] Cash Flow - The net cash flow used in operating activities for the six months ended June 30, 2024, was RMB (28,956,000), compared to RMB (21,278,000) for the same period in 2023, indicating a worsening cash flow situation[7] - The company reported a net cash outflow from investing activities of RMB (927,000) for the six months ended June 30, 2024, compared to RMB (2,663,000) in the same period of 2023[7] - The company's cash and bank balances decreased to RMB 35.1 million from RMB 63.4 million as of December 31, 2023[40] Expenses - The cost of goods sold and services provided for the six months ended June 30, 2024, was RMB 75,297,000, an increase from RMB 72,470,000 in the same period of 2023[15] - Total expenses for the period were RMB 2,212,000, compared to RMB 1,841,000 for the same period in 2023, representing an increase of approximately 20.2%[18] - The total tax expense for the period was RMB 2,169,000, slightly down from RMB 2,201,000 in the previous year[18] Employee and Workforce - As of June 30, 2024, the total employee cost for the group was approximately RMB 52.1 million, an increase from RMB 47.7 million in the same period last year, reflecting a growth of 7%[47] - The group employed a total of 554 full-time employees as of June 30, 2024, compared to 530 employees a year earlier, indicating a growth in workforce of approximately 4.5%[47] - The company emphasizes the importance of employee training and regularly reviews its compensation policies to maintain competitive salary levels[47] - The board believes that employees are one of the company's most important assets, contributing significantly to its success[47] Research and Development - Research and development expenses increased to approximately RMB 16.9 million, a rise of about 5.6% from RMB 16 million in the same period last year, with 50 Class II products registered and 9 new products under development[36] Corporate Governance - An audit committee has been established to review and supervise the company's financial reporting procedures and internal control systems, consisting of four independent non-executive directors[56] - The company has applied the principles and applicable code provisions of the Corporate Governance Code during the reporting period, with regular reviews of governance policies[57] - The company did not comply with certain provisions of the GEM Listing Rules regarding internal audit functions due to its operational scale and structure, but has implemented sufficient measures for risk management and internal control[58] Shareholder Information - The largest shareholder, Beijing Pusai Asset Management Co., Ltd., holds 31,308,576 shares, representing 38.93% of the company's domestic shares and 21.64% of the total registered capital[50] - Chen Peng, a director, holds 11,330,334 shares, accounting for 14.09% of the company's domestic shares and 7.83% of the total registered capital[50] - Chen Zhengyong, another director, owns 10,000,000 shares, which is 12.43% of the domestic shares and 6.91% of the total registered capital[50] Compliance and Regulatory Matters - The company announced non-compliance with the GEM Listing Rules related to transactions with Anhui Guoke Kangyi Medical Technology Co., Ltd., involving total amounts of approximately RMB 16.99 million, RMB 5.05 million, and RMB 1.61 million for respective periods[59] - The board is unaware of any information that needs to be disclosed under the GEM Listing Rules after reasonable inquiries during the reporting period[60]
中生北控生物科技(08247) - 2024 - 中期业绩